Zelira Therapeutics Limited (ZLDAF)

Zelira Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-3.63	-36.57	-5.57	-11.95	-8.55
Depreciation & Amortization	0.27	0.48	0.55	0.59	0.47
Asset Writedown & Restructuring Costs	-1.15	29.83	-1.14	-1.29	-1.38
Loss (Gain) From Sale of Investments	-	-	-	0.07	0.18
Stock-Based Compensation	-1.19	0.04	0.4	2.69	1.3
Provision & Write-off of Bad Debts	-	-	-1.46	1.51	-
Other Operating Activities	-0.2	0.11	-0.89	-0.36	-0.08
Change in Accounts Receivable	0.18	-0.21	0.28	-0.12	-0.12
Change in Inventory	0.77	0.28	0.36	-1.09	-0.87
Change in Accounts Payable	0.04	1.67	0.23	0.53	0.43
Operating Cash Flow	-4.91	-4.39	-7.25	-9.43	-8.62
Investment in Securities	-	-	0.74	-	-
Other Investing Activities	1.15	0.92	2.09	-0.21	1.38
Investing Cash Flow	1.15	0.92	2.83	-0.21	1.38
Short-Term Debt Issued	1.09	3.92	-	-	-
Long-Term Debt Issued	2.1	-	-	-	-
Total Debt Issued	3.19	3.92	-	-	-
Net Debt Issued (Repaid)	3.19	3.92	-	-	-
Issuance of Common Stock	-	-	1.77	7.1	10.62
Other Financing Activities	-0	-	-	-	-0.09
Financing Cash Flow	3.19	3.92	1.77	7.1	10.53
Foreign Exchange Rate Adjustments	-0.02	-0.02	0.05	0.31	-0.02
Miscellaneous Cash Flow Adjustments	-	-	-	-	-0
Net Cash Flow	-0.58	0.44	-2.6	-2.22	3.27
Free Cash Flow	-4.91	-4.39	-7.25	-9.43	-8.62
Free Cash Flow Margin	-747996.04%	-4621.90%	-2407.36%	-611.91%	-1299.02%
Free Cash Flow Per Share	-0.43	-0.39	-0.72	-1.17	-1.30
Cash Interest Paid	0.33	0.04	0.03	-	-
Levered Free Cash Flow	-0.76	-4.02	-2.64	-5.69	-4.72
Unlevered Free Cash Flow	-0.51	-3.55	-2.59	-5.66	-4.69
Change in Working Capital	0.99	1.73	0.86	-0.69	-0.56

Source: S&P Global Market Intelligence. Standard template. Financial Sources.